GSK's New CEO Charts Course Through Patent Cliff, Forecasts 2026 Growth Slowdown
In his inaugural strategic outlook, GSK's new CEO Luke Miels signaled a deliberate shift towards pipeline expansion to navigate the impending patent expiries of key HIV drugs, projecting a moderation in sales growth for 2026.